Innovative Approaches in Managing Irritable Bowel Syndrome: From Personalized Medicine to Gut Microbiome Therapies

Irritable Bowel Syndrome (IBS) is a multifaceted gastrointestinal disorder characterized by chronic abdominal pain, altered bowel habits, and a significant impact on quality of life. Recent advancements in understanding IBS pathophysiology have highlighted the role of the gut-brain axis, immune dysregulation, and gut microbiota imbalance, paving the way for innovative therapeutic approaches. This review explores personalized medicine and gut microbiome therapies as transformative strategies for IBS management. Personalized medicine leverages genetic, epigenetic, and clinical data to tailor treatments, ensuring optimal efficacy while minimizing adverse effects. Concurrently, gut microbiome-targeted therapies, including probiotics, prebiotics, fecal microbiota transplantation (FMT), and dietary modifications, aim to restore microbial equilibrium and alleviate symptoms. Emerging evidence suggests that these approaches address symptom variability and provide a long-term solution for managing IBS subtypes. Additionally, advancements in digital health tools, such as mobile applications and wearable devices, enhance symptom tracking and patient engagement. Despite promising results, challenges persist, including the need for standardized protocols, robust clinical trials, and cost-effective implementation. This review underscores the potential of integrating personalized medicine with microbiome-centered interventions to redefine IBS treatment paradigms. Future research should focus on unraveling IBS heterogeneity, refining therapeutic strategies, and addressing unmet patient needs for holistic care. Key words: Irritable Bowel Syndrome (IBS), Personalized Medicine, Gut Microbiome Therapies, Gut-Brain Axis, Probiotics and Fecal Microbiota Transplantation.